DDrare: Database of Drug Development for Rare Diseases

41. 巨細胞性動脈炎
［臨床試験数：108，薬物数：111（DrugBank：32），標的遺伝子数：33，標的パスウェイ数：121］

Searched query = "Giant cell arteritis", "Temporal arteritis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 18F-FDG; ABT-494; AIN457; ANAKINRA; Abatacept; Adalimumab; Alendronate; Alendronate versus alfacalcidol (1-alpha OH vitamin D); Alfacalcidol; Anakinra; Anti-thymocyte globulin; BOSENTAN MYLAN; Baricitinib; Blood samples; Bosentan; CNTO 136; CORTANCYL; Combination Product: mavrilimumab; Cortancyl; Cortancyl ® 1 mg; Cortancyl ® 20 mg; Cortancyl ® 5 mg; Corticoids+ tocilizumab 8mg/Kg/4 weeks; Corticosteroid (CS); Corticosteroids; Corticosteroids for Systemic Use; Cosentyx; Cyclophosphamide; Cyclosporine; Diagnostic Test: 68-Ga HA-DOTATATE PET/CT; Dotatate; Encorton; Filgrastim; GSK2973327; Gevokizumab; Glucocorticoid Treatment; Glucocorticoids; Guselkumab; Hydroxychloroquine; Infliximab; KINERET; KPL-301; Kevzara; Kevzara ®; Kineret; Lodotra; Lodotra (delayed release prednisolone); MAVRILIMUMAB; METOJECT; Mavrilimumab; Methotrexate; Methotrexate treatment; Methylprednisolone; Naltrexone; Naltrexone Hydrochloride; Nivolumab; Other: 18F-FDG PET/CT; Other: IV steroids combination alone; Other: Questionnaires; Other: questionnaires; Over encapsulated prednisone; PET10; PET3; PREDNISOLONE; PREDNISONE; Pr; PredniSONE Tablets USP, 1 mg; PredniSONE Tablets USP, 2.5 mg; PredniSONE Tablets USP, 5 mg; PredniSONE Tablets, USP; Prednisolon 1 mg JENAPHARM; Prednisolon 5 mg JENAPHARM; Prednisolone; Prednisolone 5 mg JENAPHARM; Prednisone; Prednisone Capsules; Prednisone Tablets, USP; Prednisone and ustekinumab treatment; Prednisone therapy and pharmacokinetic; Prednisone treatment; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Rituximab; Ro 001-9265; Ro 001-9265/F02; Ro 001-9265/F03; Ro 001-9265/F04; Ro 487-7533/F10-04; RoActemra; RoActemra 162 mg solution for injection in pre-filled syringe; S78989; SAR153191; SARILUMAB; SECUKINUMAB; Sarilumab; Sarilumab SAR153191; Secukinumab; Secukinumab 300 mg, s.c.; Sirukumab; TOCILIZUMAB; TOCILIZUMAB SC; Tocilizumab; Tocilizumab + Glucocorticoids (GCs); Tocilizumab SC; Tocilizumab and IV steroids combination; Tocilizumab treatment; Treatment; Upadacitinib; Ustekinumab; Vitamin D; XOMA 052

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00430807 (ClinicalTrials.gov)	January 2002	31/1/2007	Hydroxychloroquine in Giant Cell Arteritis	Multicentric Double Blind Versus Placebo Randomised Study Evaluating the Corticosteroid Sparing Effect of Hydrocyschloroquine in Non Complicated Giant Cell Arteritis.	Giant Cell Arteritis	Drug: hydroxychloroquine/placebo	University Hospital, Toulouse	NULL	Completed	18 Years	85 Years	Both	75	Phase 3	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00430807
(ClinicalTrials.gov)

January 2002

31/1/2007

Hydroxychloroquine in Giant Cell Arteritis

Multicentric Double Blind Versus Placebo Randomised Study Evaluating the Corticosteroid Sparing Effect of Hydrocyschloroquine in Non Complicated Giant Cell Arteritis.

Giant Cell Arteritis

Drug: hydroxychloroquine/placebo

University Hospital, Toulouse

NULL

Completed

18 Years

85 Years

Both

Phase 3

France